JAZZ - ジャズ・ファ―マシュ―ティカルズ (Jazz Pharmaceuticals plc) ジャズ・ファ―マシュ―ティカルズ

 JAZZのチャート


 JAZZの企業情報

symbol JAZZ
会社名 Jazz Pharmaceuticals Plc (ジャズ・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 ジャズ・ファーマシューティカル(Jazz Pharmaceuticals plc)(旧名:アズール・ファーマ(Azur Pharma Public Limited Company))は専門のバイオ医薬品会社。同社の市販製品は米国食品医薬品局(FDA)の認可を受けたナルコレプシー患者における脱力発作と日中の過度の眠気向けの治療薬である「Xyrem」(ナトリウムオキシベート経口液剤)、治療抵抗性統合失調症の治療に適応されるクロザピン口腔内崩壊錠である精神医学薬品のFazaClo(クロザピンUSP)LDとFazaClo HD、強迫性障害の治療のために市販される「Luvox CR」(フルボキサミンマレイン酸塩)、及び難治性の重度慢性疼痛の治療に適応される非オピオイド性髄腔内鎮痛剤である「Prialt」(ジコノチド髄腔内注射剤)を含む。平成24年6月、同社はEUSA Pharmaを買収した。平成24年10月、同社はMedaに女性健康事業を売却した。同社の市販製品は「Elestrin」(エストラジオールゲル)、「Gastrocrom」(クロモグリク酸ナトリウム、USP)、「Natelle One」(出産前のビタミン剤)及び「AVC Cream」を含む。   ジャズ・ファ―マシュ―ティカルズは、アイルランドのバイオ医薬品企業。医療ニ―ズに対応した製品の開発、商業化を手掛ける。ナルコレプシ―、血液学/腫瘍学、疼痛、精神医学の分野で承認済み製品を提供。おもな製品はナルコレプシ―治療薬のXyrem、急性リンパ芽球性白血病の治療薬Erwinazeなど。   Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
本社所在地 Fourth Floor Waterloo Exchange Waterloo Road Dublin 4 IRL
代表者氏名 Bruce C. Cozadd ブルース・C・コザッド
代表者役職名 Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号 +353 1-634-7800
設立年月日 37681
市場名 NASDAQ National Market System
ipoyear 2007年
従業員数 1210人
url www.jazzpharmaceuticals.com
nasdaq_url https://www.nasdaq.com/symbol/jazz
adr_tso
EBITDA EBITDA(百万ドル) 734.07800
終値(lastsale) 162.02
時価総額(marketcap) 9787490158.96
時価総額 時価総額(百万ドル) 9423.223
売上高 売上高(百万ドル) 1793.346
企業価値(EV) 企業価値(EV)(百万ドル) 10199.843
当期純利益 当期純利益(百万ドル) 278.94500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Jazz Pharmaceuticals PLC revenues increased 23% to $945.1M. Net income decreased 28% to $138.3M. Revenues reflect Royalties and contract revenues increase of 15% to $8.2M. Net income was offset by Selling general and administrative - Ba increase of 39% to $327.8M (expense) Intangible asset amortization increase from $51.9M to $108M (expense).

 JAZZのテクニカル分析


 JAZZのニュース

   Ingles stars as Jazz dispatch Grizzlies  2020/08/05 22:26:26 Seven News
Australian Joe Ingles and Mike Conley have starred for the Utah Jazz in a 124-115 win over the Memphis Grizzlies on Wednesday.
   Jazz Pharmaceuticals Announces Second Quarter 2020 Financial Results  2020/08/04 20:05:00 PR Newswire
DUBLIN, Aug. 4, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2020 and updated its 2020 financial guidance. "I am proud that we delivered strong financial and operational results above our expectations despite…
   Preview: Jazz Pharmaceuticals's Earnings  2020/08/03 12:12:00 Benzinga
Jazz Pharmaceuticals (NASDAQ: JAZZ) announces its next round of earnings this Tuesday, August 04. Here is Benzinga's everything-that-matters guide …
   Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates  2020/07/31 19:56:58 Benzinga
July turned out to be a mixed month for FDA approvals. Endo International PLC's (NASDAQ: ENDP ) cellulite treatment, Osmotica Pharmaceuticals PLC's (NASDAQ: OSMT ) eye disorder drug and Jazz Pharmaceuticals PLC's (NASDAQ: JAZZ ) drug to treat excessive daytime sleepiness were among those which successfully cleared the FDA hurdle. A few others, including Verrica Pharmaceuticals Inc (NASDAQ: VRCA ) and Eagle Pharmaceuticals Inc (NASDAQ: EGRX ), are forced to wait. The regulatory agency handed down a complete response letter for Verrica's viral skin infection treatment, while Eagle Pharma's PDUFA date for its exertional heat stroke drug was postponed until Aug. 8 due to FDA's reallocation of resources due to COVID-19. Four new molecular entities, or NMEs, were approved in July, taking the total number of NME approvals for the year to 29. Here are the key PDUFA dates scheduled for August. GSK Seeks To Expand Use Of Triple Combo Drug To Asthma Company: GlaxoSmithKline plc (NYSE: GSK ) Type of Application: sNDA Candidate: Trelegy Elypta Indication: asthma Date: Aug. 2 (estimated based on the 10-review period from the regulatory application filing date of Oct. 2) Trelegy Elypta is a single inhaled triple therapy consisting of fluticasone furoate/umeclidinium/vilanterol) and has already been approved for chronic obstructive pulmonary disease.
   Jazz's Donovan Mitchell shares bulletproof vest with police brutality victims' names stitched in  2020/07/31 11:25:10 Fox News
Utah Jazz star Donovan Mitchell, fresh off a win Thursday night against the New Orleans Pelicans, brought a bulletproof vest with him to media availability after the game.
   Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates  2020/05/05 22:45:14 Zacks Investment Research
Jazz (JAZZ) delivered earnings and revenue surprises of -31.82% and -0.68%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Jazz Pharmaceuticals Announces First Quarter 2020 Financial Results  2020/05/05 20:05:00 PR Newswire
DUBLIN, May 5, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2020 and updated 2020 financial guidance. "During this unprecedented time, I am proud of the commitment of our Jazz employees to supporting the continued…
   Should You Buy Jazz Pharmaceuticals (JAZZ) Ahead of Earnings?  2020/05/04 14:57:00 Zacks Investment Research
Jazz Pharmaceuticals (JAZZ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
   Jazz Pharmaceuticals Stops Enrollment in Phase 3 Study Evaluating Defibrotide for the Prevention of Veno-Occlusive Disease  2020/04/29 20:05:00 PR Newswire
DUBLIN, April 29, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that enrollment in the Phase 3 clinical study of defibrotide for the prevention of hepatic veno-occlusive disease (VOD) post-hematopoietic stem-cell transplantation (HSCT) in high-risk or very…
   Jazz Stars From All Over World to Support Russian Doctors Amid Pandemic in Online Marathon  2020/04/28 20:18:48 UrduPoint
   Why Is Jazz (JAZZ) Down 18% Since Last Earnings Report?  2020/03/26 15:30:34 Zacks Investment Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Jazz's (JAZZ) Xyrem Follow-On Candidate NDA Gets FDA Acceptance  2020/03/26 13:59:00 Zacks Investment Research
The FDA accepts Jazz's (JAZZ) regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem in the United States.
   FDA accepts Jazz Pharma's application for JZP-258, action date July 21  2020/03/25 20:19:42 Seeking Alpha
Under Priority Review status, the FDA has accepted Jazz Pharmaceuticals' (NASDAQ:JAZZ) marketing application for JZP-258 for the treatment of cataplexy or
   The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment  2020/03/11 12:03:52 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Aytu Bioscience Inc (NASDAQ: AYTU ) ( announced a deal to distribute COVID-19 test) Centogene NV (NASDAQ: CNTG ) Forty Seven Inc (NASDAQ: FTSV ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 10) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Alkermes Plc (NASDAQ: ALKS ) Allena Pharmaceuticals Inc (NASDAQ: ALNA ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANI Pharmaceuticals Inc (NASDAQ: ANIP ) Anixa Biosciences Inc (NASDAQ: ANIX ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Aptinyx Inc (NASDAQ: APTX ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Atossa Therapeutics Inc (NASDAQ: ATOS ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) AxoGen, Inc Common Stock (NASDAQ: AXGN ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Bausch Health Companies Inc (NYSE: BHC ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) BENITEC BIOPHAR/S ADR (NASDAQ: BNTC ) BioLife Solutions Inc (NASDAQ: BLFS ) bluebird bio Inc (NASDAQ: BLUE ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Capricor Therapeutics Inc (NASDAQ: CAPR ) Celcuity Inc (NASDAQ: CELC ) Cerecor Inc (NASDAQ: CERC ) Chembio Diagnostics Inc (NASDAQ: CEMI ) Eiger Biopharmaceuticals Inc (NASDAQ: EIGR ) Enochian Biosciences Inc (NASDAQ: ENOB ) Entasis Therapeutics Holdings Inc (NASDAQ: ETTX ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evolus Inc (NASDAQ: EOLS ) Exicure Inc (NASDAQ: XCUR ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Gossamer Bio Inc (NASDAQ: GOSS ) Gritstone Oncology Inc (NASDAQ: GRTS ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Heron Therapeutics Inc (NASDAQ: HRTX ) Incyte Corporation (NASDAQ: INCY ) INmune Bio Inc (NASDAQ: INMB ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) Jaguar Health Inc (NASDAQ: JAGX ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kura Oncology Inc (NASDAQ: KURA ) Lantheus Holdings Inc (NASDAQ: LNTH ) TapImmune Inc.
   The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index  2020/03/10 13:19:55 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Enzo Biochem, Inc. (NYSE: ENZ ) Centogene NV (NASDAQ: CNTG ) Inovio Pharmaceuticals Inc (NASDAQ: INO ) Spherix Inc (NASDAQ: SPEX ) ( added to Friday's advance on clinching an option agreement for coronavirus treatment) Down In The Dumps (Biotech stocks that hit 52-week lows March 9.) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc. (NASDAQ: AKRX ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alexion Pharmaceuticals, Inc.

 関連キーワード  (医薬品 米国株 ジャズ・ファ―マシュ―ティカルズ JAZZ Jazz Pharmaceuticals plc)

 twitter  (公式ツイッターやCEOツイッターなど)